Abstract
The feed-forward loop between the transcription factors Ppar-gamma and C/ebp-alpha is critical for lineage commitment during adipocytic differentiation. Ppar-gamma interacts with epigenetic cofactors to activate C/ebp-alpha and the downstream adipocytic gene expression program. Therefore, knowledge of the epigenetic cofactors associated with Ppar-gamma, is central to understanding adipocyte differentiation in normal differentiation and disease. We found that Prmt6 is present with Ppar-gamma on the Ppar-gamma and C/ebp-alpha promoter. It contributes to the repression of C/ebp-alpha expression, in part through its ability to induce H3R2me2a. During adipocyte differentiation, Prmt6 expression is reduced and the methyltransferase leaves the promoters. As a result, the expression of Ppar-gamma and C/ebp-alpha is upregulated and the adipocytic gene expression program is established. Inhibition of Prmt6 by a small molecule enhances adipogenesis, opening up the possibility of epigenetic manipulation of differentiation. Our data provide detailed information on the molecular mechanism controlling the Ppar-gamma–C/ebp-alpha feed-forward loop. Thus, they advance our understanding of adipogenesis in normal and aberrant adipogenesis.
Similar content being viewed by others
Introduction
The differentiation of mesenchymal stroma cells (MSC) into distinct cell lineages such as adipocytes and osteocytes is accompanied by the timely establishment of cell-type specific gene expression. Adipogenesis and osteogenesis are in a tightly controlled balance and disturbance of this equilibrium is the cause of bone-related disease. Notably, progenitor cells have the ability to differentiate into either the adipocytic or the osteocytic lineage. Remarkably, the competing gene expression programs are initially repressed until cell-type specific transcription factors initiate the respective differentiation program.
C/ebpβ Pparγand C/ebpα are key transcription factors in early adipogenesis. They regulate each other and recruit epigenetic cofactors to their target genes to drive adipogenesis. However, in progenitor cells, they can also exert a repressive function in conjunction with epigenetic cofactors, such as histone deacetylases (HDACs) and protein arginine methyltransferases (PRMTs)1,2,3,4,5,6,7.
Recently, a role for protein arginine methyltransferase 6 (PRMT6) in the repression of the erythroid gene expression program in hematopoietic progenitor cells has been described8,9,10. Prmt6 might have a similar function in adipocytic progenitors as it associates with Ppar γ, a key transcription factor in early adipogenesis3. The methyltransferase can methylate arginine residues in non-histone and histone proteins. The ability of Prmt6 to methylate arginine-2 of histone-3 (H3R2me2a) is well studied, it represses gene expression by counteracting the establishment of the activating H3K4me3 mark11,12,13,14. However, it can also perform context-dependent activating functions15,16,17. Prmt6 is recruited to target genes by site-specific transcription factors, such as RUNX1, the estrogen receptor, the androgen receptor, NF-kB9,17,18,19 and Pparγ3.
The notion that Prmt6 is associated with Pparγon the adipocytic Fabp4 gene led us to investigate the repressive function of the Prmt6/Pparγgene regulatory complex. The transcription factors Pparγand C/ebpα form a feed-forward loop in adipogenesis20,21,22,23,24. However, this feed-forward loop is repressed in progenitor cells by an unknown mechanism. The observation that Pparγand Prmt6 are associated3, suggests that the corepressor activity of Prmt6 has a role in controlling the activity of the regulatory loop between Pparγand C/ebpα.
Here, we investigate the impact of Prmt6 on the cross-regulation between Pparγand C/ebpα during adipogenesis. Our data show that Prmt6 is a corepressor of Ppar γ, regulating its own gene expression and the C/ebpα expression. In particular, Prmt6 induces the repressive epigenetic marking H3R2me2a at the C/ebpα locus. In this way, Prmt6 represses the feed-forward-loop between Pparγand C/ebpα and keeps adipogenesis in check. Upon differentiation, Prmt6 leaves the promoter, repression is released and the proadipogenic feed-forward loop is initiated. Our results provide novel insight into how adipogenesis is controlled at the epigenetic level. This finding may be valuable for the development of epigenetic substances to influence differentiation in a therapeutic setting.
Materials and methods
Cell culture
HEK293T cells (DSMZ, Braunschweig, Germany) were cultured in DMEM GlutaMAX medium (Gibco, Waltham, MA, USA), ST2 cells (DSMZ)25 in RPMI 1640 GlutaMAX medium (Gibco) supplemented with 10% fetal calf serum (FCS) and 1% Penicillin/Streptomycin (Gibco). The cells were cultured at 37 °C in a 5% CO2 atmosphere. At regular intervals, the cell culture was tested as mycoplasma-free. For Prmt6 inhibition, the selective inhibitor SGC6870 (Sigma, Darmstadt, Germany) and the control compound SGC6870N were used in a concentration of 5 µM26. For Prmt6 overexpression and knockout experiments, ST2 cells were transduced with Prmt6-LeGOiG2 or gRNA’s in lentiCRISPRv2 vector. Generation and production of virus was done as described27. LeGOiG2 empty vector and a vector expressing non-specific gRNA served as controls, respectively. The gRNA sequences are listed in the Supplemental Material Table 1.
Immunofluorescence and microscopy
ST2 cells were grown on collagen-coated coverslips. Subsequently, they were washed with PBS, fixed with 4% formaldehyde for 10 min at room temperature and washed. Permeabilization was performed by incubation with 0.1% Triton-X 100 (Carl Roth, Karlsruhe, Germany) in PBS for 5 min. Blocking was achieved using 5% BSA in PBS for 30 min. The cells were stained with primary antibodies, washed, and incubated with labeled secondary antibodies. Nuclei were stained with DAPI, cytoplasmatic F-Actin was stained with labelled Phalloidin (iFluor555, Abcam, Amsterdam, Netherlands). The cells were mounted with Fluoramount-G (Invitrogen, Waltham, MA, USA) and analyzed using an LSM710 (Zeiss, Oberkochen, Germany). Antibodies are given in the Supplemental Material Table 8.
Adipogenic differentiation and Oil-Red-O Staining
ST2 cells25 were seeded at a density of 15,000 cells per cm2 and grown in adipogenic differentiation medium (DMEM GlutaMAX supplemented with 9% FCS, 250 nM dexamethasone (Sigma-Aldrich, Darmstadt, Germany), 450 µM IBMX (Santa Cruz Biotechnology, Dallas, Texas, USA), 1 µM rosiglitazone (Sigma; Darmstadt, Germany), 5 µg/ml human insulin (Gibco, Waltham, MA, USA). After adipogenic induction, cells were washed with PBS and fixed in 4% formaldehyde for 10 min. Subsequently, cells were rinsed with 60% isopropanol and the wells were dried prior to the addition of Oil-Red-O (Sigma-Aldrich, Darmstadt, Germany). The lipid droplet formation was analyzed by microscopy. For quantification, the Oil-Red-O was extracted from the stained cells with 100% isopropanol and the absorbance was analyzed at 500 nm in a plate reader (Tecan Group Ltd., Maennedorf, Switzerland).
Chromatin immunoprecipitation (ChIP) assay
Chromatin immunoprecipitation (ChIP) assays were performed according to the X-ChIP protocol from Abcam. DNA purification was done with the ChIP DNA Clean & Concentrator Kit (Zymo Research, Freiburg, Germany). All experiments were performed with at least two different chromatin preparations. Oligonucleotides used for ChIP-qPCR and antibodies are given in the Supplemental Material Tables 4 and 7.
Co-immunoprecipitation (Co-IP)
HEK293T cells were transfected with 6 µg DNA (Flag-PRMT6-pcDNA3.1, PPARγ1-pcDNA3, PPARγ2-pcDNA3, pcDNA3 empty vector). Whole cell extracts were prepared using lysis buffer [50 mM Tris–HCl (pH 7.5), 150 mM sodium chloride, 10 mM sodium fluoride, 20 mM ß-glycerophosphate, 1% IGEPAL and 1 mM EDTA supplemented with protease inhibitor cocktail (Carl Roth, Karlsruhe, Germany) and 100 mM sodium orthovanadate. After incubation for 10 min, 7.5 mM Magnesium Chloride and 50 U Benzonase were added. The lysate was then incubated on a rotating wheel for 2 h at 4 °C followed by centrifugation at 14.000 rpm for 10 min at 4 °C. Protein concentration was determined by Bradford assay (Bio-Rad Laboratories, Feldkirchen, Germany). 600 µg whole cell lysate and 50 µl Pierce Anti-DYKDDDDK magnetic Agarose-Beads (Thermo Fisher Scientific: Waltham, Massachusetts, USA) were used per IP. The reactions were incubated for 2 h on a rotating wheel at 4°C. The beads were washed twice with lysis buffer and subsequently boiled in 2 × Laemmli buffer for 5 min. The supernatant was applied to a 10% SDS-PAGE and analyzed by immunoblotting.
Reverse transcription–quantitative polymerase chain reaction (RT-qPCR)
RNA was extracted using the Quick-RNA Miniprep Kit (Zymo Research, Freiburg, Germany) according to the manufacturer’s instruction. cDNA was synthesized with 1 µg RNA using the First-Strand cDNA Synthesis Kit (Invitrogen). qPCR amplification was performed using 1 µl cDNA, 10 µl SYBR Green Mix with ROX additive (Biozym Scientific, Oldendorf, Germany), 1 µl primer mix (10 µM) and 8 µl RNase-free water. Data analysis was performed according to the ΔΔCT method. TBP expression was used as housekeeping gene. Oligonucleotides used for the PCR are given (Supplemental Material Table 2 and 3).
Immunoblotting
Protein samples were separated by SDS-PAGE and transferred with a wet blot system (Bio-Rad Laboratories, Feldkirchen, Germany) using standard techniques. Primary antibodies are listed in the Supplemental Material Tables 5 and 6.
Histone extraction
ST2 cells were harvested and washed with ice-cold PBS. For histone extraction, 107 cells/ml were resuspended in Triton extraction buffer (PBS containing 0.5% Triton X 100 (v/v), 2 mM phenylmethylsulfonyl fluoride (PMSF), 0.02% (w/v) NaN3). Cells were lysed for 10 min on ice with gentle stirring. After a centrifugation at 650 × g for 10 min at 4 °C, the pellet containing nuclei was washed with half the volume of buffer. At a density of 4 × 107 nuclei/ml the Pellet was resuspended in 0.2N HCl. Histones were acid extracted over night at 4°C. To remove debris, samples were centrifugated as before. The supernatant was neutralized with 2 M NaOH at 1/10 of the volume. Histone lysates were stored at − 80 °C.
GST-pulldown
500 ng plasmid-DNA of PPARγ2-pcDNA3(2HA) was used in the TNT T7 Quick coupled transcription/translation system (Promega GmbH: Walldorf, Germany), supplemented with35S-Methionine (10mCi/ml, 1000Ci/mmol; Hartmann Analytic, Braunschweig, Germany). 10 µl of the in vitro translation was incubated with either GST or GST-PRMT6 beads for 3 h at 4 °C on a rotating wheel27. After centrifugation at 2300 rpm for 1 min the pellet was lysed followed by a 10 min incubation at 4 °C on a rotating wheel. This was repeated twice. Samples were denatured at 95 °C with 1.5 × Laemmli buffer. Proteins were separated by SDS-PAGE. The gel was stained with Coomassie-blue. The dried gel was analyzed by phosphorimaging.
Statistics
Experiments were performed in at least three independent replicates. Results were analyzed using the GraphPad Prism software. Data are presented as mean ± standard error. Statistical significance was calculated using Student’s t-test or ANOVA (analysis of variance). As post-hoc statistical test the Holm-Šídák test was used.
Results
Expression of Prmt6 during adipogenesis
To examine the localization of Prmt6 during adipogenesis we performed immunofluorescence staining for Prmt6. Prmt6 was present in the nucleus of undifferentiated ST2 cells and with lower staining intensity upon 14 days of adipocyte differentiation (Fig. 1A, Supplemental Figure S1). Interestingly, Prmt6 expression at the mRNA level was transiently increased during differentiation (Fig. 1B, Supplemental Figure S2, 3), whereas Prmt6 expression was reduced at the protein level consistent with the immunofluorescence data (Fig. 1C). In agreement with the notion that Prmt6 was down regulated during adipogenesis, we found relatively low Prmt6 levels in adipocytic cells in publicly available single cell datasets (Supplemental Figure S4). The adipocytic master regulators Pparγand C/ebpα were upregulated during adipogenesis (Fig. 1D) and adipocyte markers were increased (Supplemental Figure S5, 6).
To examine if the downregulation of Prmt6 is crucial for adipogenesis, we overexpressed Prmt6 (Supplemental Figure S7). Prmt6 expression led to reduced lipid droplet formation (Supplemental Figure S8) compared to the control. Analysis of the Pparγisoforms revealed that Pparγ1 expression was reduced in the uninduced state and remained lower in Prmt6 expressing cells upon induction of adipogenesis (Fig. 1E). Importantly, the expression of the adipocyte-specific isoform Pparγ2 was decreased upon differentiation in Prmt6 overexpressing cells (Fig. 1F). Furthermore, C/ebpα expression was reduced (Fig. 1G). Consequently, the expression of the downstream adipocytic genes Adipoq (Adiponectin), Fabp4 and Adipsin, was lower in Prmt6 expressing cells (Fig. 1F). Taken together, Prmt6 expression was decreased during adipogenesis. Adipogenesis and the expression of the key regulators Pparγ and C/ebpα were reduced upon Prmt6 overexpression.
Loss of Prmt6 increases C/ebpα and Pparγ expression
Overexpression of Prmt6 suppressed adipogenesis (Fig. 1). To further investigate the influence of Prmt6 on C/ebpα and Pparγ expression Prmt6 was knocked out using CRISPR/Cas9 (Fig. 2A, Supplemental Figure S9). Loss of Prmt6 resulted in an increased Pparγ expression during differentiation (Fig. 2B). Furthermore, C/ebpα expression was increased (Fig. 2C). The expression of the adipocyte marker gene Fabp4 was augmented in the Prmt6 knockout cells (Fig. 2D).
Subsequently, we used the Prmt6 inhibitor SGC6870 to inhibit endogenous Prmt6 activity. Prmt6 inhibition reduced H3R2me2 (Fig. 2E, Supplemental Figure S9). Furthermore, Prmt6 inhibition resulted in increased Pparγ1 and Pparγ2 expression (Fig. 2F, G) and to a pronounced increase in C/ebpα expression (Fig. 2H, Supplemental Figure S10). Accordingly, the adipocyte-specific gene Fabp4 was augmented upon inhibitor treatment at day three of differentiation (Fig. 2I) and lipid droplets were already visible at day three of differentiation in the treated cells (Fig. 2J). These data suggest that loss of Prmt6 increases the potential for adipocytic differentiation by affecting the expression of C/ebpα and Pparγ.
Interaction of Prmt6 with Pparγ
Inhibition of Prmt6 increased the expression of C/ebpα, which is a prominent target gene of Pparγ2 during adipocyte differentiation. This supports the notion that Prmt6 is recruited to the C/ebpα promoter by Pparγ3. To determine whether Pparγ1 and Ppary2 are able to associate with Prmt6, we performed coimmunoprecipitation (CoIP). CoIP was performed using anti-Flag beads to precipitate Flag-Prmt6. Western blot with an anti-Pparγ antibody showed that both isoforms co-precipitated with Prmt6 (Fig. 3A, Supplemental Figure S11). The interaction of Prmt6 with Pparγ was verified in a GST pull-down experiment with recombinant GST-Prmt6 and in vitro translated S35 labeled Pparγ (Fig. 3B, Supplemental Figure S12).
Subsequently, we performed chromatin immunoprecipitation (ChIP) of endogenous Pparγ and Prmt6 at the C/ebpα promoter in ST2 cells. We detected Pparγ and Prmt6 close to the transcription start site of the C/ebpα gene (Fig. 3C). To determine if Pparγ and Prmt6 concomitantly occupy the C/ebpα promoter, we performed ChIP-ReChIP and detected both at the C/ebpα promoter (Fig. 3D). Pparγ and PRMT6 were also present at the Pparγ promoter (Fig. 3E, F). At a control region, no binding was detected in ChIP-ReChIP (Fig. 3G). These data demonstrate that Pparγ and Prmt6 are present together at the Pparγ promoter and the C/ebpα promotor in the undifferentiated state in ST2 cells.
Cofactor exchange at the C/ebpα promoter
Our data show that Prmt6 negatively affects the expression of the Pparγ target gene C/ebpα and counteracts adipogenesis. Thus, we examined the Pparγ/Prmt6 complex at the C/ebpα promoter before and after adipocytic differentiation. As expected, the amount of Pparγ increased upon differentiation (Fig. 4A). Prmt6 binding was reduced (Fig. 4B). Furthermore, binding of the corepressor Hdac1 was reduced in the differentiated cells (Fig. 4C). Concomitantly to reduced Hdac1 amount, binding of the coactivator CBP to the C/ebpα promoter was increased (Fig. 4D). At the histone level, H3R2me2a was reduced at the C/ebpα promoter upon adipocytic differentiation (Fig. 4E). The activating histone modification H3K4me3 was already present in the uninduced state and increased upon differentiation (Fig. 5F). These data indicate that chromatin at the C/ebpα promoter is not in a repressed state in undifferentiated cells. This is consistent with our observation that Pparγ and C/ebpα are expressed to some level in these cells (Fig. 1).
To further analyze the influence of Prmt6 on the state of the C/ebpα promoter we knocked out Prmt6 using CRISPR/Cas9. Reduction of Prmt6 was detected at the C/ebpα promoter upon knockout (Fig. 4G). In addition, Hdac1 binding was reduced (Fig. 4H) and binding of CBP was increased (Fig. 4I). These data indicate that Prmt6 levels at the C/ebpα promoter influence the presence of corepressors and coactivators.
C/ebpα promoter is poised for a signal from the Pparγ-Cebpα feed-forward loop
We have shown that Prmt6 interacts with Pparγ and is recruited to the C/ebpα promoter with Pparγ. To further investigate the function of Pparγ with Prmt6 during adipocytic differentiation, we knocked out Pparγ using CRISPR/Cas9. Upon knockout of Pparγ (Fig. 5A, Supplemental Figure S13), Pparγ was no longer induced upon adipocyte differentiation (Fig. 5B, C). In agreement with the observation that Pparγ is a main activator of C/ebpα, the increase of C/ebpα expression upon differentiation was also absent in the Pparγ knockout cells (Fig. 5D). RNApolII is present at the C/ebpα promoter in the non-differentiated cells (Fig. 5E). Upon loss of Pparγ expression the presence of RNApolII on the C/ebpα promoter is reduced to some degree (Fig. 5E). However, the phosphorylated form of RNApolII, which is the transcriptionally active form of the enzyme is reduced substantially in the Pparγ knockout cells (Fig. 5F). Consequently, adipocytic differentiation as evaluated by lipid droplet formation was reduced upon Pparγ knockout (Fig. 5G). Accordingly, expression of C/ebpα target gene Fabp4 was reduced (Fig. 5H). These data indicate that the C/ebpα promoter is in a poised state in before differentiation is executed. Taken together, our data show that Prmt6 is part of a regulatory mechanism which controls the Pparγ-Cebpα feed-forward loop in progenitor cells (Fig. 5I, J).
Discussion
Adipocytic progenitor cells are in a delicate balance between adipogenic and osteogenic differentiation. In the progenitor population both cell-type specific gene expression programs can be initiated, but are repressed until differentiation is induced. We found that Prmt6 antagonizes the activation of a Pparγ-C/ebpα feed-forward loop, which controls adipogenesis (Fig. 5G, H). This way Prmt6 contributes to repression of the adipogenic gene expression program in progenitor cells.
Prmt6 is reduced during adipogenesis
Prmt6 is present in the nucleus and is downregulated upon induction towards adipogenesis. Downregulation was detected at the protein level, whereas Prmt6 levels were transiently increased at the mRNA level (Fig. 1). This could indicate posttranscriptional regulation of Prmt6, potentially by an adipocyte associated microRNA. Alternatively, Prmt6 transcript stability could be regulated by RNA-methylation as was recently described for Prmt628. There is also evidence for regulation of Prmt6 by proteasomal degradation29,30. In our hands, treatment of proteasome inhibitor MG132 did not lead to an increased Prmt6 protein level in ST2 cells (Supplemental Figure S3). At the pre-adipocyte state of differentiation, Pparγ and C/ebpα are expressed at a low level (Fig. 1).
In case the downregulation of Prmt6 was inhibited by Prmt6 over-expression, the activation of the adipocyte specific transcription factors Pparγ and C/ebpα was reduced. As a consequence, adipocytic gene expression and adipogenesis was reduced. This indicates that the observed downregulation of Prmt6 during adipocyte differentiation has a physiological role. Prmt6 might keep the adipocytic gene expression in check. This way progenitors can maintain the potential to differentiate into distinct cell types and only upon down-regulation the adipocytic potential is released. Thus, it would be interesting to study the role of Prmt6 during osteocyte differentiation, which is in a balance with adipocytic differentiation.
Loss of Prmt6 augments adipogenesis
Prmt6 has a profound effect on the differentiation of distinct cell types10,31 and knockdown of Prmt6 by shRNA increases adipocyte differentiation3. Likewise, knockout of Prmt6 by CRISPR/Cas9 led to increased Pparγ and C/ebpα expression. Furthermore, inhibition of Prmt6 by a small-molecule inhibitor augmented adipogenesis (Fig. 2). Prmt6 interacts with Pparγ and is present with the transcription factor on the C/ebpα and the Pparγ promoter (Fig. 3). This indicates that Prmt6 influences the Pparγ-C/ebpα circuit at several levels (Fig. 5). Upon induction of adipocyte differentiation, we observed that the amount of Pparγ increased at the C/ebpα promoter (Fig. 4). Whereas Prmt6 and Hdac1 are reduced at the C/ebpα promoter upon differentiation. Concomitantly, the coactivator CBP is recruited. This observation supports the notion that Prmt6 is a corepressor associated with Pparγ, which is exchanged by coactivating cofactors (Reviewed in32). A similar observation has been made by us in case of a RUNX1-PRMT6 complex in megakaryocytic differentiation9. Because Pparγ expression and binding to the C/ebpα promoter significantly increases upon differentiation, the formation of a novel regulatory complex is likely. Pparγ complex formation might also be influenced by posttranslational modification of the transcription factor. Notably, Pparγ can be methylated by the protein arginine methyl transferase 4 (PRMT4)33. However, no evidence was found for methylation of PPARγ by PRMT63.
Prmt6 activity maintains C/ebpα in an activatable state
We found the activating histone marks H3K4me3 already present in undifferentiated cells at the C/ebpα locus. This is in line with the notion, that the formation of an active chromatin environment precedes activation of genes expression during adipocytic differentiation34,35,36. However, the repressive H3R2me2a, which is mediated by Prmt6 is reduced upon differentiation and H3K4me3 is augmented. H3R2me2a counteracts the establishment of H3K4me3. There is an interplay between arginine methyl transferases and lysine demethylases. KDM1A promotes adipocyte differentiation through repressing Wnt signaling, which is important for osteogenic differentiation37. As PRMT6 and KDM1A interact38,39, it is conceivable that PRMT6 and KDM1A concomitantly regulate the branching between adipogenesis and osteogenesis. Further studies are required to investigate a potentially PRMT6-KDM1A-axis. Loss of the Prmt6 protein does not alter C/ebpα expression in the undifferentiated cells but enhances its activation upon induction of differentiation (Fig. 2). Furthermore, the presence of Hdac1 is reduced and CBP is increased upon loss of Prmt6. This could be caused by a role of Prmt6 as a scaffold protein, which contributes to Hdac1 binding. Alternatively, Prmt6 could methylate transcription factors in its proximity and this way alter cofactor recruitment, as has been shown for the transcription factor Runx1 and Prmt140.
Knockout of Pparγ leads to decreased adipocytic identity
Pparγ is a central adipocytic lineage-determining factor41,42,43 and it is cooperating with C/ebpα20,22,44. We firmly established that Pparγ is present with Prmt6 on its own promoter and the C/ebpα promoter. In agreement with the presence of H3K4me3 at the C/ebpα promoter in the non-differentiated state, we also detected RNApolII at the promoter, although expression of C/ebpα was low (Fig. 5). This indicates that the adipocytic gene expression program is in a pre-activated state in progenitor cells. Our data show that loss of Pparγ leads to a breakdown of the adipocytic gene expression program (Fig. 5). These results indicate, that Prmt6 has a role in adipocytic progenitor cells, before the Pparγ–C/ebpα feed-forward loop is activated. It suppresses the Pparγ–C/ebpα feed-forward loop (Fig. 5), but leaves it activatable. Manipulation of this regulatory loop through Prmt6 inhibition could be a route to influence differentiation in a therapeutic setting.
Data availability
Data are provided within the manuscript and the supplementary information files; this includes full-length blots. Please contact the corresponding author Jörn Lausen (J.L) to request data or material from this study.
References
LeBlanc, S. E., Wu, Q., Lamba, P., Sif, S. & Imbalzano, A. N. Promoter-enhancer looping at the PPARgamma2 locus during adipogenic differentiation requires the Prmt5 methyltransferase. Nucl. Acids Res. 44, 5133–5147. https://doi.org/10.1093/nar/gkw129 (2016).
LeBlanc, S. E. et al. Protein arginine methyltransferase 5 (Prmt5) promotes gene expression of peroxisome proliferator-activated receptor gamma2 (PPARgamma2) and its target genes during adipogenesis. Mol. Endocrinol. 26, 583–597. https://doi.org/10.1210/me.2011-1162 (2012).
Hwang, J. W., So, Y. S., Bae, G. U., Kim, S. N. & Kim, Y. K. Protein arginine methyltransferase 6 suppresses adipogenic differentiation by repressing peroxisome proliferatoractivated receptor gamma activity. Int. J. Mol. Med. 43, 2462–2470. https://doi.org/10.3892/ijmm.2019.4147 (2019).
Hu, Y. J. et al. Transcriptional and post-transcriptional control of adipocyte differentiation by Jumonji domain-containing protein 6. Nucl. Acids Res. 43, 7790–7804. https://doi.org/10.1093/nar/gkv645 (2015).
Picard, F. et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 429, 771–776. https://doi.org/10.1038/nature02583 (2004).
Yadav, N. et al. CARM1 promotes adipocyte differentiation by coactivating PPARgamma. EMBO Rep. 9, 193–198. https://doi.org/10.1038/sj.embor.7401151 (2008).
Gelman, L. et al. p300 interacts with the N- and C-terminal part of PPARgamma2 in a ligand-independent and -dependent manner, respectively. J. Biol. Chem. 274, 7681–7688. https://doi.org/10.1074/jbc.274.12.7681 (1999).
Kuvardina, O. N. et al. RUNX1 represses the erythroid gene expression program during megakaryocytic differentiation. Blood 125, 3570–3579. https://doi.org/10.1182/blood-2014-11-610519 (2015).
Herglotz, J. et al. Histone arginine methylation keeps RUNX1 target genes in an intermediate state. Oncogene 32, 2565–2575. https://doi.org/10.1038/onc.2012.274 (2013).
Herkt, S. C. et al. Protein arginine methyltransferase 6 controls erythroid gene expression and differentiation of human CD34(+) progenitor cells. Haematologica 103, 18–29. https://doi.org/10.3324/haematol.2017.174516 (2018).
Guccione, E. et al. Methylation of histone H3R2 by PRMT6 and H3K4 by an MLL complex are mutually exclusive. Nature 449, 933–937. https://doi.org/10.1038/nature06166 (2007).
Kirmizis, A. et al. Arginine methylation at histone H3R2 controls deposition of H3K4 trimethylation. Nature 449, 928–932. https://doi.org/10.1038/nature06160 (2007).
Hyllus, D. et al. PRMT6-mediated methylation of R2 in histone H3 antagonizes H3 K4 trimethylation. Genes Dev. 21, 3369–3380. https://doi.org/10.1101/gad.447007 (2007).
Iberg, A. N. et al. Arginine methylation of the histone H3 tail impedes effector binding. J. Biol. Chem. 283, 3006–3010. https://doi.org/10.1074/jbc.C700192200 (2008).
Harrison, M. J., Tang, Y. H. & Dowhan, D. H. Protein arginine methyltransferase 6 regulates multiple aspects of gene expression. Nucl. Acids Res. 38, 2201–2216. https://doi.org/10.1093/nar/gkp1203 (2010).
Casadio, F. et al. H3R42me2a is a histone modification with positive transcriptional effects. Proc. Natl. Acad. Sci. USA 110, 14894–14899. https://doi.org/10.1073/pnas.1312925110 (2013).
Di Lorenzo, A., Yang, Y., Macaluso, M. & Bedford, M. T. A gain-of-function mouse model identifies PRMT6 as a NF-kappaB coactivator. Nucl.ic Acids Res. 42, 8297–8309. https://doi.org/10.1093/nar/gku530 (2014).
Sun, Y., Chung, H. H., Woo, A. R. & Lin, V. C. Protein arginine methyltransferase 6 enhances ligand-dependent and -independent activity of estrogen receptor alpha via distinct mechanisms. Biochim. Biophys. Acta 2067–2078, 2014. https://doi.org/10.1016/j.bbamcr.2014.04.008 (1843).
Scaramuzzino, C. et al. Protein arginine methyltransferase 6 enhances polyglutamine-expanded androgen receptor function and toxicity in spinal and bulbar muscular atrophy. Neuron 85, 88–100. https://doi.org/10.1016/j.neuron.2014.12.031 (2015).
Lefterova, M. I. et al. PPARgamma and C/EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale. Genes Dev. 22, 2941–2952. https://doi.org/10.1101/gad.1709008 (2008).
Nielsen, R. et al. Genome-wide profiling of PPARgamma:RXR and RNA polymerase II occupancy reveals temporal activation of distinct metabolic pathways and changes in RXR dimer composition during adipogenesis. Genes Dev. 22, 2953–2967. https://doi.org/10.1101/gad.501108 (2008).
Madsen, M. S., Siersbaek, R., Boergesen, M., Nielsen, R. & Mandrup, S. Peroxisome proliferator-activated receptor gamma and C/EBPalpha synergistically activate key metabolic adipocyte genes by assisted loading. Mol. Cell. Biol. 34, 939–954. https://doi.org/10.1128/MCB.01344-13 (2014).
Rauch, A. & Mandrup, S. Transcriptional networks controlling stromal cell differentiation. Nat. Rev. Mol. Cell. Biol. 22, 465–482. https://doi.org/10.1038/s41580-021-00357-7 (2021).
Tontonoz, P. & Spiegelman, B. M. Fat and beyond: The diverse biology of PPARgamma. Annu. Rev. Biochem. 77, 289–312. https://doi.org/10.1146/annurev.biochem.77.061307.091829 (2008).
Abdallah, B. M., Alzahrani, A. M., Abdel-Moneim, A. M., Ditzel, N. & Kassem, M. A simple and reliable protocol for long-term culture of murine bone marrow stromal (mesenchymal) stem cells that retained their in vitro and in vivo stemness in long-term culture. Biol. Proced. Online 21, 3. https://doi.org/10.1186/s12575-019-0091-3 (2019).
Shen, Y. et al. A first-in-class, highly selective and cell-active allosteric inhibitor of protein arginine methyltransferase 6. J. Med. Chem. 64, 3697–3706. https://doi.org/10.1021/acs.jmedchem.0c02160 (2021).
Schneider, L. et al. PRMT6 activates cyclin D1 expression in conjunction with the transcription factor LEF1. Oncogenesis 10, 42. https://doi.org/10.1038/s41389-021-00332-z (2021).
Cheng, Y. et al. Decoding m(6)A RNA methylome identifies PRMT6-regulated lipid transport promoting AML stem cell maintenance. Cell. Stem Cell. 30, 69–85. https://doi.org/10.1016/j.stem.2022.12.003 (2023).
Chen, W. et al. SCF-FBXO24 regulates cell proliferation by mediating ubiquitination and degradation of PRMT6. Biochem. Biophys. Res. Commun. 530, 75–81. https://doi.org/10.1016/j.bbrc.2020.06.007 (2020).
Li, T. et al. F-box protein FBXW17-mediated proteasomal degradation of protein methyltransferase PRMT6 exaggerates CSE-induced lung epithelial inflammation and apoptosis. Front. Cell. Dev. Biol. 9, 599020. https://doi.org/10.3389/fcell.2021.599020 (2021).
Lee, Y. H. et al. Protein arginine methyltransferase 6 regulates embryonic stem cell identity. Stem Cells Dev. 21, 2613–2622. https://doi.org/10.1089/scd.2011.0330 (2012).
Viswakarma, N. et al. Coactivators in PPAR-regulated gene expression. PPAR Res. https://doi.org/10.1155/2010/250126 (2010).
Zhong, Y. et al. PRMT4 facilitates white adipose tissue browning and thermogenesis by methylating PPARgamma. Diabetes 72, 1095–1111. https://doi.org/10.2337/db22-1016 (2023).
Mikkelsen, T. S. et al. Comparative epigenomic analysis of murine and human adipogenesis. Cell 143, 156–169. https://doi.org/10.1016/j.cell.2010.09.006 (2010).
Siersbaek, R. et al. Extensive chromatin remodelling and establishment of transcription factor “hotspots” during early adipogenesis. EMBO J. 30, 1459–1472. https://doi.org/10.1038/emboj.2011.65 (2011).
Sarusi Portuguez, A. et al. Hierarchical role for transcription factors and chromatin structure in genome organization along adipogenesis. FEBS J. 284, 3230–3244. https://doi.org/10.1111/febs.14183 (2017).
Wang, D., Kuang, Y. L., Zhang, G. L., Xiao, K. & Liu, Y. L. Lysine-specific demethylase 1 in energy metabolism: A novel target for obesity. J. Nutr. 152, 1611–1620. https://doi.org/10.1093/jn/nxac080 (2022).
Prakasam, R. et al. LSD1/PRMT6-targeting gene therapy to attenuate androgen receptor toxic gain-of-function ameliorates spinobulbar muscular atrophy phenotypes in flies and mice. Nat. Commun. https://doi.org/10.1038/s41467-023-36186-9 (2023).
Musri, M. M. et al. Histone demethylase LSD1 regulates adipogenesis. J. Biol. Chem. 285, 30034–30041. https://doi.org/10.1074/jbc.M110.151209 (2010).
Zhao, X. et al. Methylation of RUNX1 by PRMT1 abrogates SIN3A binding and potentiates its transcriptional activity. Genes Dev. 22, 640–653. https://doi.org/10.1101/gad.1632608 (2008).
Hu, E., Tontonoz, P. & Spiegelman, B. M. Transdifferentiation of myoblasts by the adipogenic transcription factors PPAR gamma and C/EBP alpha. Proc. Natl. Acad. Sci. U.S.A. 92, 9856–9860. https://doi.org/10.1073/pnas.92.21.9856 (1995).
Tontonoz, P., Hu, E. & Spiegelman, B. M. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79, 1147–1156. https://doi.org/10.1016/0092-8674(94)90006-x (1994).
Rosen, E. D. et al. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol. Cell. 4, 611–617. https://doi.org/10.1016/s1097-2765(00)80211-7 (1999).
Wu, Z. et al. Cross-regulation of C/EBP alpha and PPAR gamma controls the transcriptional pathway of adipogenesis and insulin sensitivity. Mol. Cell. 3, 151–158. https://doi.org/10.1016/s1097-2765(00)80306-8 (1999).
Acknowledgements
We would like to thank Sylvia Weiss and Franziska Gekeler for assistance. We also thank Prof. T. Kufer for the donation of plasmids. The authors gratefully acknowledge the Technology Platform “Cellular Analytics” of the Stuttgart Research Center Systems Biology for their support & assistance in this work.
Funding
Open Access funding enabled and organized by Projekt DEAL.
Author information
Authors and Affiliations
Contributions
J.L. and M.G. wrote the main manuscript text and J.L. prepared the figures. M.G., V.H, J.F, B.H and L.W. performed experiments and analyzed data. J.L. conceived and supervised the study. All authors reviewed the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare that they have no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Gerstner, M., Heller, V., Fechner, J. et al. Prmt6 represses the pro-adipogenic Ppar-gamma–C/ebp-alpha transcription factor loop. Sci Rep 14, 6656 (2024). https://doi.org/10.1038/s41598-024-57310-9
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41598-024-57310-9
- Springer Nature Limited